Guardant Health Receives First Commercial Payor Coverage For Guardant Reveal Test From Blue Cross And Blue Shield Of Louisiana
Portfolio Pulse from Happy Mohamed
Guardant Health, Inc. (NASDAQ:GH) announced that Blue Cross and Blue Shield of Louisiana will now cover its Guardant Reveal molecular residual disease (MRD) test. The test, which detects circulating tumor DNA in blood after treatment, will be covered for individuals with stage II or III colorectal cancer after curative treatment. The coverage is effective from July 10 and is aligned with monitoring guidelines established by the National Comprehensive Cancer Network for colorectal cancer.
July 20, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's Guardant Reveal test will now be covered by Blue Cross and Blue Shield of Louisiana, potentially increasing the usage and revenue of the test.
The coverage of Guardant Health's test by a major insurance provider like Blue Cross and Blue Shield of Louisiana could lead to increased usage of the test by colorectal cancer patients. This could potentially increase the revenue generated from the test, positively impacting Guardant Health's financial performance in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100